Thursday, 29th February CD1-MR1 2024
Scientific Program 11 - Tumour Immunity
9:00AM - 10:30AM
Thursday, 29th February
Grand Ballroom
Chairs: Amy Courtney & Johan Sandberg
- Adoptive cell therapy of hematological malignancies across MHC-barriers by iNKT cells engineered with a CD1c-restricted TCR - Giulia Casorati
- Clinical application of iPS cell-derived NKT cells to cancer immunotherapy - Shinichiro Motohashi
- Selective mitochondrial Complex I disruption induces NKT cell mediated tumor immunogenicity - Tevis Vitale
- Characterising MAIT cell function in vivo in models of glioblastoma - Eleanor M Eddy
- The anti-tumour effector function of mucosal-associated invariant T cells is impaired by fatty acids and aberrant lipid metabolism - Katrin Böttcher
- Optimizing adoptive immunotherapy of leukemia with CD1c-redirected T cells - Michela Consonni
Morning Tea
10:30AM - 11:00AM
Thursday, 29th February
Mezzanine Level
Scientific Program 12 - Immunotherapies and Vaccines
11:00AM - 12:30PM
Thursday, 29th February
Grand Ballroom
Chairs: Paolo Dellabona & Deborah Lewinsohn
Sponsored by:
- Title: Cancer Immunotherapy with CAR-Redirected NKT Cells - Leonid S Metelitsa
- Harnessing the potential of CAR-iNKT cells to treat cancer - Nicole van der Weerden
- Allogeneic iNKT cells as clinical platform in a range of disease settings - Mark Exley
- NKT cell adjuvanted mRNA vaccines induce liver-resident memory T cells that protect against malaria - Gavin F Painter
- Allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy - Lili Yang
Conclusion & Awards
12:30PM - 1:45PM
Thursday, 29th February
Grand Ballroom